<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05068973</url>
  </required_header>
  <id_info>
    <org_study_id>LUCIOLA 2020_10_02</org_study_id>
    <nct_id>NCT05068973</nct_id>
  </id_info>
  <brief_title>Evaluation of the NOVATECH ® LUCIOLA TM EB Fiducial Marker During Radiotherapy Sessions in Lung Cancer Patients</brief_title>
  <acronym>LUCIOLA</acronym>
  <official_title>Evaluation of the Performance and Tolerance of the NOVATECH ® LUCIOLA TM EB Fiducial Marker During Radiotherapy Sessions in Patients Suffering From Lung Cancer: Multicenter, Post CE-mark Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital St. Joseph, Marseille, France</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>NOVATECH SA</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hospital St. Joseph, Marseille, France</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Following CE certification, this Post Market Clinical Follow-up investigates the performance&#xD;
      and safety of using the new fiducial marker, NOVATECH® LUCIOLA™ EB, in the lung airways to&#xD;
      monitor in real-time tumor location during radiotherapy.&#xD;
&#xD;
      At the time of insertion near the tumor, the Luciola's 3 fiducial marker arms are deployed&#xD;
      simultaneously. Optimal detection of the fiducial marker is considered during the&#xD;
      radiotherapy treatment.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      NOVATECH® LUCIOLA™ EB fiducial marker will be implanted near the lung tumor by bronchial&#xD;
      endoscopy by a pulmonologist. Following a dosimetry visit, participants will be proposed a&#xD;
      maximum of 5 radiation therapy sessions. A follow-up visit at 3 months will take place after&#xD;
      the last radiotherapy session. The participation period for each participant will be between&#xD;
      4.5 and 6 months. This study will evaluate the Luciola implant's performance and safety&#xD;
      (visibility, migration, complications, tumoral response).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 22, 2021</start_date>
  <completion_date type="Anticipated">July 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">March 1, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>LUCIOLA implant's performance during radiotherapy (RT) treatment: tracking rate</measure>
    <time_frame>Takes place 4-6 weeks after implantation</time_frame>
    <description>Number of RT sessions during which the LUCIOLA implant was used for treatment in relation to the total number of RT sessions.&#xD;
If LUCIOLA can be detected and used for treatment, the patient will attend 3 to 5 RT sessions over a period lasting 1 to 2 weeks.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Luciola implant &quot;visibility&quot;</measure>
    <time_frame>From the dosimetry visit (week 2-4 after implantation) to the last RT session (3-4 weeks after dosimetry)</time_frame>
    <description>Average of the visibility rate (number of visible LUCIOLA implant arm(s) (0,1,2 or 3) compared to the total number of LUCIOLA implant arms (3)) for all the LUCIOLA implants for the entire radiotherapy treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Global migration rate</measure>
    <time_frame>Dosimetry CT-Scan takes place 2-4 weeks after implantation; End of treatment CT-Scan takes place 12 weeks after last radiotherapy session</time_frame>
    <description>Number of LUCIOLA implants which have migrated between the beginning (dosimetry visit) and end of treatment follow-up (12 weeks after last radiotherapy session) in relation to the total number of LUCIOLA implants</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>4.5 to 6 months (from implantation to the end of participant's enrollment in the study)</time_frame>
    <description>Occurrence rate of adverse or unexpected events which took place between implantation and up to 3 months following the RT treatment's end.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Replanning radiotherapy treatment</measure>
    <time_frame>During radiotherapy sessions (4-6 weeks after implantation)</time_frame>
    <description>Replanning rate = Number of replanning versus total number of sessions for all of the participants.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Radiotherapist's satisfaction</measure>
    <time_frame>End of study visit: 12 weeks after last radiotherapy session</time_frame>
    <description>Number of participants for whom the radiotherapist is &quot;satisfied&quot; in relation to the total number of participants.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulmonologist's satisfaction</measure>
    <time_frame>Within 24 hours after implantation</time_frame>
    <description>Number of procedures at the end of which the pulmonologist is &quot;satisfied&quot; in relation to the total number of procedures&#xD;
The following questions will be considered:&#xD;
Easy introduction of the LUCIOLA delivery system in the guide sheath&#xD;
Easy placement (release) of the LUCIOLA device at the implantation site&#xD;
Change of the position after LUCIOLA implant release</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumoral response</measure>
    <time_frame>Between the inclusion CT-Scan (8 weeks prior to implantation at the most) and the radiotherapy end of treatment CT-Scan (12 weeks after last RT session)</time_frame>
    <description>Tumoral response rate according to RECIST criteria between the inclusion CT-Scan and the radiotherapy end of treatment CT-Scan.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">35</enrollment>
  <condition>Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Luciola</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Bronchoscopic implantation of the fiducial marker NOVATECH® LUCIOLA™ EB prior to radiotherapy treatment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>NOVATECH® LUCIOLA™ EB - (Fiducial Marker)</intervention_name>
    <description>Bronchoscopic implantation in the lung of the NOVATECH® LUCIOLA™ EB fiducial marker</description>
    <arm_group_label>Luciola</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Participants ≥ 18 years of age&#xD;
&#xD;
          -  Participants with primary, secondary or metastatic lung cancer with an indication for&#xD;
             radiotherapy and placement of a fiducial marker&#xD;
&#xD;
          -  Participants who will be able to tolerate the flexible bronchoscopic implantation&#xD;
             procedure and radiotherapy treatment.&#xD;
&#xD;
          -  Participants who give their written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Participants with uncontrolled infection / participants with active infections.&#xD;
&#xD;
          -  Participants with a bronchoscopy contra-indication&#xD;
&#xD;
          -  Pregnant or breast-feeding women&#xD;
&#xD;
          -  Participants with known allergy to one of the components (tantalum and nickel titanium&#xD;
             alloy for the marker and polymer materials which are contained in the delivery device)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bruno Escarguel, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hôpital Saint Joseph, Marseille France</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Roomila NAECK</last_name>
    <phone>0033786904408</phone>
    <email>luciola@hopital-saint-joseph.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Rahamia AHAMADA</last_name>
    <phone>0033488731071</phone>
    <email>luciola@hopital-saint-joseph.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hopital Saint Joseph</name>
      <address>
        <city>Marseille</city>
        <zip>13008</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Roomila Naeck, PhD</last_name>
      <phone>+ 33 (0)7 86 90 44 08</phone>
      <email>Luciola@hopital-saint-joseph.fr</email>
    </contact>
    <contact_backup>
      <last_name>Rahamia Ahamada</last_name>
      <phone>+ 33 (0)4 88 73 10 71</phone>
      <email>Luciola@hopital-saint-joseph.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Bruno Escarguel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>September 20, 2021</study_first_submitted>
  <study_first_submitted_qc>September 30, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 6, 2021</study_first_posted>
  <last_update_submitted>October 29, 2021</last_update_submitted>
  <last_update_submitted_qc>October 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hospital St. Joseph, Marseille, France</investigator_affiliation>
    <investigator_full_name>ESCARGUEL Bruno</investigator_full_name>
    <investigator_title>Pulmonologist</investigator_title>
  </responsible_party>
  <keyword>Fiducial marker</keyword>
  <keyword>Bronchoscopy</keyword>
  <keyword>SBRT</keyword>
  <keyword>Radiotherapy</keyword>
  <keyword>NOVATECH LUCIOLA EB</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

